Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
235.02
+5.68 (2.48%)
May 26, 2026, 2:29 PM EDT - Market open

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Revenue from Intangible Royalty Assets
143.88M132.53M95.33M
Revenue from Intangible Royalty Assets Growth
8.56%39.03%13.61%
Income from Financial Royalty Assets
32.59M28.47M13.44M
Income from Financial Royalty Assets Growth
14.49%111.75%1181.60%
Royalties Revenue
176.47M161.00M108.77M
Royalties Revenue Growth
9.61%48.02%28.03%
Captisol Revenue
35.41M40.21M30.88M
Captisol Revenue Growth
-11.95%30.21%8.85%
Contract Revenue and Income
62.60M66.87M27.48M
Contract Revenue and Income Growth
-6.39%143.38%52.79%
Revenue (Total)
274.48M268.09M167.13M
Revenue (Total) Growth
2.38%60.40%27.28%
Updated May 8, 2026. Data Source: Fiscal.ai.